Dual-drug amorphous formulation of gliclazide

References

• Newman A, Reutzel-Edens SM, Zografi G. Coamorphous active pharmaceutical ingredient-small molecule mixtures: considerations in the choice of coformers for enhancing dissolution and oral bioavailability. J Pharm Sci. 2018;107(1):5–17.
   PubMed Web of Science ®Google Scholar
• Laitinen R, Löbmann K, Grohganz H, et al. Supersaturating drug delivery systems: the potential of co-amorphous drug formulations. Int J Pharm. 2017;532(1):1–12.
   PubMedGoogle Scholar
• Grohganz H, Priemel PA, Löbmann K, et al. Refining stability and dissolution rate of amorphous drug formulations. Expert Opin Drug Deliv. 2014;11(6):977–989.
   PubMed Web of Science ®Google Scholar
• Jensen KT, Löbmann K, Rades T, et al. Improving co-amorphous drug formulations by the addition of the highly water soluble amino acid, proline. Pharmaceutics. 2014;6(3):416–435.
   PubMedGoogle Scholar
• Löbmann K, Grohganz H, Laitinen R, et al. Amino acids as co-amorphous stabilizers for poorly water soluble drugs-Part 1: preparation, stability and dissolution enhancement. Eur J Pharm Biopharm. 2013;85(3 Pt B):873–881.
   PubMed Web of Science ®Google Scholar
• Laitinen R, Löbmann K, Grohganz H, et al. Amino acids as co-amorphous excipients for simvastatin and glibenclamide: physical properties and stability. Mol Pharm. 2014;11(7):2381–2389.
   PubMed Web of Science ®Google Scholar
• Jensen KT, Blaabjerg LI, Lenz E, et al. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts. J Pharm Pharmacol. 2016;68(5):615–624.
   PubMed Web of Science ®Google Scholar
• Lu Q, Zografi G. Phase behavior of binary and ternary amorphous mixtures containing indomethacin, citric acid, and PVP. Pharm Res. 1998;15(8):1202–1206.
   PubMed Web of Science ®Google Scholar
• Hoppu P, Jouppila K, Rantanen J, et al. Characterisation of blends of paracetamol and citric acid. J Pharm Pharmacol. 2007;59(3):373–382.
   PubMed Web of Science ®Google Scholar
• Ali AMA, Ali AA, Maghrabi IA. Clozapine-carboxylic acid plasticized co-amorphous dispersions: preparation, characterization and solution stability evaluation. Acta Pharm. 2015;65(2):133–146.
   PubMed Web of Science ®Google Scholar
• Han Y, Pan Y, Lv J, et al. Powder grinding preparation of co-amorphous β-azelnidipine and maleic acid combination: molecular interactions and physicochemical properties. Powder Technol. 2016;291:110–120.
   Web of Science ®Google Scholar
• Teja A, Musmade PB, Khade AB, et al. Simultaneous improvement of solubility and permeability by fabricating binary glassy materials of Talinolol with Naringin: solid state characterization, in-vivo in-situ evaluation. Eur J Pharm Sci. 2015;78:234–244.
   PubMed Web of Science ®Google Scholar
• Shayanfar A, Ghavimi H, Hamishekar H, et al. Coamorphous atorvastatin calcium to improve its physicochemical and pharmacokinetic properties. J Pharm Pharm Sci. 2013;16(4):577–587.
   PubMed Web of Science ®Google Scholar
• Qian S, Heng W, Wei Y, et al. Co-amorphous lurasidone hydrochloride-saccharin with charge-assisted hydrogen bonding interaction shows improved physical stability and enhanced dissolution with pH-independent solubility behavior. Cryst Growth Des. 2015;15(6):2920–2928.
   Web of Science ®Google Scholar
• Gao Y, Liao J, Qi X, et al. Coamorphous repaglinide-saccharin with enhanced dissolution. Int J Pharm. 2013;450(1–2):290–295.
   PubMed Web of Science ®Google Scholar
• Gniado K, Löbmann K, Rades T, et al. The influence of co-formers on the dissolution rates of co-amorphous sulfamerazine/excipient systems. Int J Pharm. 2016;504(1–2):20–26.
   PubMedGoogle Scholar
• Gniado K, MacFhionnghaile P, McArdle P, et al. The natural bile acid surfactant sodium taurocholate (NaTC) as a coformer in coamorphous systems: enhanced physical stability and dissolution behavior of coamorphous drug-NaTC systems. Int J Pharm. 2018;535(1–2):132–139.
   PubMedGoogle Scholar
• Laitinen R, Löbmann K, Strachan CJ, et al. Emerging trends in the stabilization of amorphous drugs. Int J Pharm. 2013;453(1):65–79.
   PubMed Web of Science ®Google Scholar
• Chavan RB, Thipparaboina R, Kumar D, et al. Co amorphous systems: a product development perspective. Int J Pharm. 2016;515(1–2):403–415.
   PubMed Web of Science ®Google Scholar
• Yamamura S, Momose Y, Takahashi K, et al. Solid-state interaction between cimetidine and naproxen. Drug Stab. 1996;1:173–178.
   Google Scholar
• Yamamura S, Gotoh H, Sakamoto Y, et al. Physicochemical properties of amorphous precipitates of cimetidine–indomethacin binary system. Eur J Pharm Biopharm. 2000;49(3):259–265.
   PubMed Web of Science ®Google Scholar
• Lodagekar A, Chavan RB, Chella N, et al. Role of valsartan as an antiplasticizer in development of therapeutically viable drug − drug coamorphous system. Cryst Growth Des. 2018;18(4):1944–1950.
   Web of Science ®Google Scholar
• Yamamura S, Gotoh H, Sakamoto Y, et al. Physicochemical properties of amorphous salt of cimetidine and diflunisal system. Int J Pharm. 2002;241(2):213–221.
   PubMedGoogle Scholar
• Löbmann K, Laitinen R, Grohganz H, et al. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen. Mol Pharm. 2011;8(5):1919–1928.
   PubMed Web of Science ®Google Scholar
• Löbmann K, Strachan C, Grohganz H, et al. Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions. Eur J Pharm Biopharm. 2012;81(1):159–169.
   PubMed Web of Science ®Google Scholar
• Dengale SJ, Ranjan OP, Hussen SS, et al. Preparation and characterization of co-amorphous Ritonavir-Indomethacin systems by solvent evaporation technique: improved dissolution behavior and physical stability without evidence of intermolecular interactions. Eur J Pharm Sci. 2014;62:57–64.
   PubMed Web of Science ®Google Scholar
• Wairkar S, Gaud R. Co-amorphous combination of nateglinide-metformin hydrochloride for dissolution enhancement. AAPS PharmSciTech. 2015;17:1–9.
   Web of Science ®Google Scholar
• Russo MG, Sancho MI, Silva LM, et al. Looking for the interactions between omeprazole and amoxicillin in a disordered phase. An experimental and theoretical study. Spectrochim Acta A Mol Biomol Spectrosc. 2016;156:70–77.
   PubMed Web of Science ®Google Scholar
• Ueda H, Kadota K, Imono M, et al. Co-amorphous formation induced by combination of tranilast and diphenhydramine hydrochloride. J Pharm Sci. 2017;106(1):123–128.
   PubMed Web of Science ®Google Scholar
• Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37(4):1053–1059.
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BEK, Lee KE, et al. The incidence of hypertension in insulin-dependent diabetes. Arch Intern Med. 1996;156(6):622–627.
   PubMedGoogle Scholar
• Skotnicki M, Gaweł A, Cebe P, et al. Thermal behavior and phase identification of Valsartan by standard and temperature-modulated differential scanning calorimetry. Drug Dev Ind Pharm. 2013;39(10):1508–1514.
   PubMed Web of Science ®Google Scholar
• Wairkar S, Gaud R. Development and characterization of microstructured, spray-dried co-amorphous mixture of antidiabetic agents stabilized by silicate. AAPS PharmSciTech. 2019;20(3):141.
   PubMed Web of Science ®Google Scholar
• Lenz E, Jensen KT, Blaabjerg LI, et al. Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin-arginine. Eur J Pharm Biopharm. 2015;96:44–52.
   PubMed Web of Science ®Google Scholar
• Pacult J, Rams-Baron M, Chmiel K, et al. How can we improve the physical stability of co-amorphous system containing flutamide and bicalutamide? The case of ternary amorphous solid dispersions. Eur J Pharm Sci. 2019;136:104947.
   PubMed Web of Science ®Google Scholar
• Knapik-Kowalczuk J, Chmiel K, Jurkiewicz K, et al. Physical stability and viscoelastic properties of co-amorphous ezetimibe/simvastatin system. Pharmaceuticals. 2019;12(1):40.
   Web of Science ®Google Scholar
• Lu T, Chen C. Uncertainty evaluation of humidity sensors calibrated by saturated salt solutions. Measurement. 2007;40(6):591–599.
   Web of Science ®Google Scholar
• Sawyer DT, Heineman WR, Beebe JM. 1984. Chemistry experiments for instrumental methods. New York, Chichester: John Wiley & Sons.
   Google Scholar
• Aljohani M, MacFhionnghaile P, McArdle P, et al. Investigation of the formation of drug-drug cocrystals and coamorphous systems of the antidiabetic drug gliclazide. Int J Pharm. 2019;561:35–42.
   PubMedGoogle Scholar
• Guinet Y, Paccou L, Danède L, et al. Structural description of the marketed form of valsartan: a crystalline mesophase characterized by nanocrystals and conformational disorder. Int J Pharm. 2017;526(1-2):209–216.
   PubMedGoogle Scholar
• Fitzpatrick S, McCabe JF, Petts CR, et al. Effect of moisture on polyvinylpyrrolidone in accelerated stability testing. Int J Pharm. 2002;246(1–2):143–151.
   PubMedGoogle Scholar